Advanced in Ulcerative Colitis

Melanie D. Beaton

London, ON, CA 
Advanced in Ulcerative Colitis
London, ON, CA 
OverviewLocationsClinical Research

Overview

Melanie Beaton practices in London, Canada. Ms. Beaton is rated as an Advanced expert by MediFind in the treatment of Ulcerative Colitis. Her top areas of expertise are Non-Alcoholic Fatty Liver Disease, Viral Gastroenteritis, Ulcerative Colitis, Endoscopy, and Colonoscopy.

Her clinical research consists of co-authoring 50 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 7 articles and participated in 1 clinical trial in the study of Ulcerative Colitis.

Gender
Female

Locations

London, ON, Canada
Other Locations
Vancouver, BC, Canada
ON, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

VERDICT: In actiVE Ulcerative Colitis, a RanDomIzed Controlled Trial for Determination of the Optimal Treatment Target
VERDICT: In actiVE Ulcerative Colitis, a RanDomIzed Controlled Trial for Determination of the Optimal Treatment Target
Enrollment Status: Active_not_recruiting
Publish Date: September 11, 2025
Intervention Type: Biological
Study Drug: Vedolizumab
Study Phase: Phase 4
Stopping Aminosalicylate Therapy in Inactive Crohn's Disease (STATIC) Study: A Randomized, Open-label, Non-inferiority Trial
Stopping Aminosalicylate Therapy in Inactive Crohn's Disease (STATIC) Study: A Randomized, Open-label, Non-inferiority Trial
Enrollment Status: Active_not_recruiting
Publish Date: May 20, 2025
Intervention Type: Other
Study Drug: Aminosalicylate
Study Phase: Phase 4
View 1 Less Clinical Trial

50 Total Publications

IL23 Receptor Polymorphism Is a Predictor of Anti-Tumour Necrosis Factor-α-Induced Paradoxical Psoriasis in Inflammatory Bowel Disease.
IL23 Receptor Polymorphism Is a Predictor of Anti-Tumour Necrosis Factor-α-Induced Paradoxical Psoriasis in Inflammatory Bowel Disease.
Journal: Alimentary pharmacology & therapeutics
Published: May 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Beaton's expertise for a condition
ConditionClose
    View All 17 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile